CD274 and head and neck squamous cell carcinoma: The expression of PD-L1 is a useful predictive biomarker for checkpoint inhibitors according to clinical trials21,32,33, and higher response rates have been observed in HNSCC patients with high levels of PD-L1 expression4,11.